专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20240159741A1 NEW TREATMENT AND PREVENTION BASED ON NEW METHOD FOR CONTROLLING CELLULAR IMMUNITY 审中-公开
公开(公告)号：US20240159741A1
公开(公告)日：2024-05-16
申请号：US18546915
申请日：2022-02-16
申请人： Ken ISHII , ZERIA PHARMACEUTICAL CO., LTD.
发明人： Ken ISHII , Burcu TEMIZOZ , Kokichi KATSUNUMA
IPC分类号： G01N33/50 , G01N33/68
CPC分类号： G01N33/5091 , G01N33/6866 , G01N2800/24 , G01N2800/52
摘要： The present disclosure provides a composition for the prophylaxis or treatment of diseases (e.g., infectious disease, allergy or autoimmune disease). The present disclosure provides a composition, a medicament, a kit, and the like for the prophylaxis or treatment of the disease of a test subject. The composition, medicament, kit, and the like contain a non-causative factor antigen component that is neither derived from nor cross-reactive with the causative factor of the disease, and is administered under conditions where a causative factor antigen component derived from and/or cross-reactive with a causative factor of the target disease is present in the target.

2. 发明授权

US11083757B2 Inhibitor for cognitive function decline 有权
公开(公告)号：US11083757B2
公开(公告)日：2021-08-10
申请号：US16345401
申请日：2017-10-27
申请人： ZERIA PHARMACEUTICAL CO., LTD.
发明人： Kotaro Yamada , Hidetomo Sakurai , Osamu Nakagawasai , Koichi Tanno
IPC分类号： A61K35/18 , A61K35/12 , A61K35/00 , A61K35/407 , A61P25/00 , A23L33/115 , A61K9/00 , A23L5/00 , A61P25/28
摘要： A cognitive decline inhibitor or a learning ability improver is provided, which comprises, as an active ingredient, a liver hydrolysate having a lipid content of less than 2 mass % or a phosphatidylcholine content of less than 1 mass %.

3. 发明申请

US20200375954A1 THERAPEUTIC AGENT FOR FOOD COMPETENCE DISORDER IN STOMACH 审中-公开
公开(公告)号：US20200375954A1
公开(公告)日：2020-12-03
申请号：US16998637
申请日：2020-08-20
申请人： ZERIA PHARMACEUTICAL CO., LTD.
发明人： Yugo MATSUNAGA , Shigeru UEKI , Hiroki KATO , Shiro KOBAYASHI
IPC分类号： A61K31/426 , C07D277/56 , C07D307/68
摘要： A therapeutic agent for impaired gastric accommodation which contains as an active ingredient a compound represented by the general formula (1): (wherein R1 represents a hydrogen atom, a hydroxyl group or a halogen atom; A represents a furyl group, a thienyl group, a thiazolyl group or an oxazolyl group; R2 and R3 each represents an alkyl group with 1 to 5 carbon atoms; and n represents an integer of 2 to 4), or an acid addition salt thereof.Use of a therapeutic agent of the present invention greatly alleviates symptoms caused by said disorders, such as early satiety and bloating, because it improves relaxation of gastric fundus and impaired gastric accommodation.

4. 发明申请

US20150374632A1 ENTERIC COATED TABLET 审中-公开
标题翻译： ENTERIC涂层片
公开(公告)号：US20150374632A1
公开(公告)日：2015-12-31
申请号：US14769660
申请日：2014-02-21
申请人： ZERIA PHARMACEUTICAL CO., LTD.
发明人： Akio RYU , Miyako OSADA
IPC分类号： A61K9/28 , A61K31/606
CPC分类号： A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K31/606
摘要： To provide an enteric coated tablet containing a large amount of medicinal ingredient and having sufficient impact resistance, without forming a thick enteric coating layer.The enteric coated tablet contains (A) a core tablet containing a medicinal ingredient and having a weight of 1,000 mg or more; (B) a coating layer containing a water-soluble polymer applied onto the surface of the core tablet; and (C) an enteric coating layer dissolving at pH 7 or higher which is applied onto the surface of the coating layer containing a water-soluble polymer, wherein the sum of the polymer amount of the coating layer (B) and the polymer amount of the coating layer (C) is 10 to 18 mg/cm2, the polymer amount of the coating layer (B) is 6 to 12 mg/cm2, and the polymer amount of the coating layer (C) is 3 to 6 mg/cm2.
摘要翻译：提供含有大量药用成分并具有足够抗冲击性的肠溶衣片剂，而不形成厚的肠溶衣层。肠溶片剂含有（A）含有药物成分并具有1,000mg以上重量的核心片剂; （B）涂布在芯片表面上的水溶性聚合物的涂层; 和（C）溶解在pH7以上的肠溶衣层，其被涂布在含有水溶性聚合物的被覆层的表面上，其中，涂布层（B）的聚合物量与聚合物的量涂层（C）的涂布层（C）为10〜18mg / cm 2，涂层（B）的聚合物量为6〜12mg / cm 2，涂层（C）的聚合物量为3〜6mg / cm 2 。

5. 发明申请

US20100286210A1 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof 有权
标题翻译：咔唑衍生物，其溶剂化物或其药学上可接受的盐
公开(公告)号：US20100286210A1
公开(公告)日：2010-11-11
申请号：US11666631
申请日：2005-10-28
申请人： Masakazu Murata , Yoshihiko Itokazu , Ryu Nakao
发明人： Masakazu Murata , Yoshihiko Itokazu , Ryu Nakao
IPC分类号： A61K31/4439 , A61K31/427 , A61K31/422 , C07D413/14 , C07D417/12 , C07D413/12 , A61P29/00 , A61P3/04 , A61P3/10 , A61P3/06 , A61P9/12 , A61P1/16 , A61P3/00
CPC分类号： C07D413/12 , C07D413/14 , C07D417/12
摘要： An object of the present invention is to provide novel carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof having an excellent adipose tissue weight reducing effect, hypoglycemic effect, and hypolipidemic effect, which are useful as a preventive and/or therapeutic agent for fatty liver, obesity, lipid metabolism abnormality, visceral adiposity, diabetes, hyperlipemia, impaired glucose tolerance, hypertension, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and the like.The above-mentioned object can be achieved by carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof, wherein the carbazole derivatives are represented by the following general formula (I): (In the formula (I), the ring A represents phenyl group or the like; X represents —O— or the like; Y represents ═N— or the like; a and b represent methylene group or the like; both V and Z represent —O— or the like; W represents a C1-C10 alkylene group whose 1 or 2 hydrogen atoms may be substituted by a phenyl group or a C1-C6 alkyl group; 1,2-phenylene group; 1,3-cyclohexyl group; or the like; R1 represents methyl group or the like; R2 represents methoxy group or the like; and R3 represents carboxy group or the like.)
摘要翻译：本发明的目的是提供具有优异的脂肪组织减重作用，降血糖作用和降血脂作用的新型咔唑衍生物，溶剂合物或其药学上可接受的盐，其可用作脂肪的预防和/或治疗剂肝脏，肥胖症，脂质代谢异常，内脏肥胖，糖尿病，高脂血症，葡萄糖耐量降低，高血压，非酒精性脂肪性肝病，非酒精性脂肪性肝炎等。上述目的可以通过其咔唑衍生物，溶剂化物或其药学上可接受的盐来实现，其中咔唑衍生物由以下通式（I）表示：（式（I）中，环A表示苯基 X表示-O-等; Y表示= N-等; a和b表示亚甲基等; V和Z均表示-O-等; W表示C1-C10 其1或2个氢原子可被苯基或C1-C6烷基取代的亚烷基; 1,2-亚苯基; 1,3-环己基;等; R1代表甲基等; R2 表示甲氧基等; R3表示羧基等。）

6. 发明申请

US20090156652A1 THERAPEUTIC AGENT FOR FOOD COMPETENCE DISORDER IN STOMACH 审中-公开
标题翻译：食品中的食物不良症状的治疗药物
公开(公告)号：US20090156652A1
公开(公告)日：2009-06-18
申请号：US12372234
申请日：2009-02-17
申请人： Yugo Matsunaga , Shigeru Ueki , Hiroki Kato , Shiro Kobayashi
发明人： Yugo Matsunaga , Shigeru Ueki , Hiroki Kato , Shiro Kobayashi
IPC分类号： A61K31/426 , A61K31/341 , A61P1/04
CPC分类号： A61K31/426 , C07D277/56 , C07D307/68
摘要： A therapeutic agent for impaired gastric accommodation which contains as an active ingredient a compound represented by the general formula (1): (wherein R1 represents a hydrogen atom, a hydroxyl group or a halogen atom; A represents a furyl group, a thienyl group, a thiazolyl group or an oxazolyl group; R2 and R3 each represents an alkyl group with 1 to 5 carbon atoms; and n represents an integer of 2 to 4), or an acid addition salt thereof.Use of a therapeutic agent of the present invention greatly alleviates symptoms caused by said disorders, such as early satiety and bloating, because it improves relaxation of gastric fundus and impaired gastric accommodation.
摘要翻译：含有作为活性成分的通式（1）表示的化合物作为活性成分的治疗剂：其中，R1表示氢原子，羟基或卤素原子，A表示呋喃基，噻吩基，噻唑基或恶唑基; R2和R3各自表示碳原子数1〜5的烷基，n表示2〜4的整数）或其酸加成盐。使用本发明的治疗剂可以大大减轻所述疾病引起的症状，如早期饱腹感和腹胀，因为这改善了胃底松弛和胃容易受损。

7. 发明授权

US6121301A Substituted benzoylaminothiazole derivatives and drugs containing the same 有权
标题翻译：取代苯甲酰氨基噻唑衍生物和含有它们的药物
公开(公告)号：US6121301A
公开(公告)日：2000-09-19
申请号：US284477
申请日：1999-04-21
申请人： Masaaki Nagasawa , Kenji Sato , Tadashi Kurimoto , Shigeru Ueki
发明人： Masaaki Nagasawa , Kenji Sato , Tadashi Kurimoto , Shigeru Ueki
IPC分类号： C07D277/46 , C07D277/56 , C07D417/12 , A61K31/425
CPC分类号： C07D417/12 , C07D277/46 , C07D277/56
摘要： The present invention relates to a substituted benzoylaminothiazole derivative represented by the following formula (I): ##STR1## wherein X represents an imino group which may be substituted by a lower alkyl group, or an oxygen atom, R.sup.1 represents a cyano group, a lower alkoxycarbonyl group, a lower alkoxycarbonylamino group, a lower alkylsulfonylamino group, a lower alkanoyl or lower alkylsulfonyl group which may be substituted by a halogen atom, a 1-ureido group, a halo-substituted lower alkyl group or a 2-pyrrolylimino group, R.sup.2 and R.sup.3 are the same or different and each independently represents a hydrogen atom or a lower alkyl group and m stands for an integer of 2 to 4, or a salt thereof; and a medicament comprising the compound as an effective ingredient. The compound of the invention is useful as a preventive and therapeutic agent for epigastric dyscomfort, nausea, vomiting, heartburn, anorexia, bellyache, abdominal flatulence, chronic gastritis or the like.
摘要翻译： PCT No.PCT / JP97 / 03774 Sec。 371 1999年4月21日第 102（e）1999年4月21日PCT PCT 1997年10月20日PCT公布。公开号WO98 / 17654 日期：1998年04月30日本发明涉及由下式（I）表示的取代苯甲酰氨基噻唑衍生物：其中X表示可被低级烷基或氧原子取代的亚氨基，R 1表示氰基，低级烷氧基羰基，低级烷氧基羰基氨基，低级烷基磺酰基氨基，可被卤素原子取代的低级烷酰基或低级烷基磺酰基，1-脲基，卤代低级烷基或2-吡咯基咪唑基，R2和R3相同或不同，各自独立地表示氢原子或低级烷基，m表示2〜4的整数，或其盐; 以及包含该化合物作为有效成分的药物。本发明的化合物可用作上腹部不适，恶心，呕吐，胃灼热，厌食，腹痛，腹胀气，慢性胃炎等的预防和治疗剂。

8. 发明授权

US5760040A Indole derivative for treating overproduction of dihydrotestosterone 失效
标题翻译：用于治疗二氢睾酮过量产生的吲哚衍生物
公开(公告)号：US5760040A
公开(公告)日：1998-06-02
申请号：US714079
申请日：1997-05-05
申请人： Kiyoshi Yoshida , Tadashi Kurimoto , Mineo Takei , Hiroki Sato
发明人： Kiyoshi Yoshida , Tadashi Kurimoto , Mineo Takei , Hiroki Sato
IPC分类号： C07D209/12 , A61K31/405 , A61K31/495 , C07D403/10
CPC分类号： C07D209/12
摘要： The present invention relates to an indole derivative represented by formula (1) or a salt thereof, and a pharmaceutical containing the derivative or the salt: ##STR1## wherein R.sup.1 represents lower alkyl; R.sup.2 represents hydrogen or phenyl which may be substituted by at least one lower alkyl, lower alkoxy or a halogen atom; R.sup.3 represents hydrogen, lower alkyl, lower alkoxy, or phenylalkyloxy which may be substituted by halogen or lower alkyl; R.sup.4 represents hydrogen, lower alkyl or lower alkoxy; R.sup.5 represents hydrogen or lower alkyl; and n represents an integer of 1 to 5. This compound has the effects of both blocking .alpha..sub.1 -adrenergic receptors and inhibiting testosterone 5.alpha.-reductases, and is useful as a remedy and/or a preventive for diseases caused by dihydrotestosterone overproduction, such as prostatic hypertrophy, and diseases accompanying the same, such as urination disorder, male pattern alopecia, acne, and so forth.
摘要翻译： PCT No.PCT / JP95 / 00599 Sec。 371日期：1997年5月5日 102（e）日期1997年5月5日PCT提交1995年3月29日PCT公布。第WO95 / 26955号公报日期：1995年10月12日本发明涉及式（1）表示的吲哚衍生物或其盐，以及含有该衍生物或其盐的药物：其中R1表示低级烷基; R2代表氢或可被至少一个低级烷基，低级烷氧基或卤原子取代的苯基; R 3表示可被卤素或低级烷基取代的氢，低级烷基，低级烷氧基或苯基烷氧基; R4代表氢，低级烷基或低级烷氧基; R5代表氢或低级烷基; 并且n表示1至5的整数。该化合物具有阻断α1-肾上腺素能受体和抑制睾酮5α-还原酶的作用，并且可用作二氢睾酮过量产生引起的疾病的补救和/或预防，例如作为前列腺肥大，以及伴随的疾病，例如排尿障碍，男性脱发，痤疮等。

9. 发明授权

US5750524A Remedy for hyperlipidemia 失效
标题翻译：高脂血症的治疗方法
公开(公告)号：US5750524A
公开(公告)日：1998-05-12
申请号：US793102
申请日：1997-02-24
申请人： Yukinori Mera , Naoki Nishi , Tadashi Kurimoto , Hiroki Sato
发明人： Yukinori Mera , Naoki Nishi , Tadashi Kurimoto , Hiroki Sato
IPC分类号： A61K31/18 , A61K31/19 , A61K31/195 , A61K31/215 , A61K31/235 , A61K31/275 , A61K31/277 , A61K31/38 , A61K31/381 , A61K31/415 , A61K31/4152 , A61K31/50 , A61K31/63 , A61P3/06 , A61P9/08 , A61P9/10 , A61P43/00 , C07D231/20 , C07D237/04 , C07D333/34 , A61K31/16 , A61K31/495
CPC分类号： C07D333/34 , A61K31/18 , A61K31/195 , A61K31/277 , A61K31/381 , A61K31/4152 , A61K31/50 , C07D231/20 , C07D237/04 , Y10S514/824
摘要： The invention relates to a remedy for hyperlipidemia, which comprises, as an active ingredient, an indane derivative represented by the general formula (1): ##STR1## wherein R.sup.1 means an alkyl group having 1-12 carbon atoms, a benzyl group, a styryl group, a naphthyl group, a phenyl group which may be substituted, or a thienyl group which may be substituted, R.sup.2 denotes a carboxyl group, an alkoxycarbonyl group having 1-4 carbon atoms, ##STR2## Y is a group represented by --(CH.sub.2).sub.p -- (p stands for an integer of 0-5), a group represented by --CO--(CH.sub.2).sub.q .about. or --CH(OH)--(CH.sub.2).sub.q .about. (q stands for an integer of 1-4, and .about. means bonding to R.sup.2), an oxymethylene group, or a vinylene group, and n stands for an integer of 1-4, or a pharmaceutically acceptable salt thereof, to use of this compound for the preparation of a remedy for hyperlipidemia, and to a method for treating hyperlipidemia by making good use of this compound.
摘要翻译： PCT No.PCT / JP95 / 01486 Sec。 371日期1997年2月24日 102（e）1997年2月24日PCT PCT 1995年7月26日PCT公布。出版物WO96 / 05820 日本特开1996年2月29日本发明涉及高脂血症的治疗方法，其包含作为活性成分的通式（1）表示的二氢吲哚衍生物：其中R 1表示具有1-12个碳原子，苄基，苯乙烯基，萘基，可被取代的苯基或可被取代的噻吩基，R2表示羧基，具有1-4个碳原子的烷氧羰基，

10. 发明授权

US5409956A Indan derivative and thromboxane antagonist containing the same 失效
标题翻译： Indan衍生物和含有相同的血栓素拮抗剂
公开(公告)号：US5409956A
公开(公告)日：1995-04-25
申请号：US107823
申请日：1993-08-30
申请人： Kiyoshi Yoshida , Yoshiaki Yamaji , Tadashi Kurimoto , Ryuichi Sato , Motoki Torizuka
发明人： Kiyoshi Yoshida , Yoshiaki Yamaji , Tadashi Kurimoto , Ryuichi Sato , Motoki Torizuka
IPC分类号： A61K31/19 , A61K31/195 , A61K31/22 , A61K31/38 , A61K31/50 , A61K38/22 , A61K38/55 , A61P9/00 , A61P43/00 , C07C311/13 , C07C311/17 , C07C311/19 , C07C311/29 , C07C311/42 , C07D231/20 , C07D237/04 , C07D333/34 , A01N37/12 , C07C311/00
CPC分类号： A61K38/2242 , A61K38/55 , A61K38/556 , C07C311/13 , C07C311/17 , C07C311/19 , C07C311/29 , C07C311/42 , C07D231/20 , C07D237/04 , C07D333/34 , C07C2102/08
摘要： The present invention relates to indan derivatives represented by the formula (1) or pharmaceutically acceptable salts thereof: ##STR1## [wherein R.sup.1 represents C1 to C12 alkyl, benzyl, styryl, naphthyl, optionally substituted phenyl or optionally substituted thienyl; R.sup.2 represents carboxyl, C1 to C4 alkoxycarbonyl, ##STR2## Y represents --(CH.sub.2).sub.p -- (wherein p represents an integer of 0 to 5), --CO--(CH.sub.2).sub.q .about., --CH(OH)--(CH.sub.2).sub.q .about., (wherein q represents an integer of 1 to 4, and the symbol .about. represents a linkage to R.sup.2), oxymethylene or ethylene; and n represents an integer of 1 to 4]. The compounds according to the present invention potently antagonize the action of thromboxane A.sub.2, and therefore useful for the treatment and prevention of diseases caused by thromboxane A.sub.2 such as angiosis, vasospasm, asthma and the like.
摘要翻译： PCT No.PCT / JP92 / 00236 Sec。 371日期：1993年8月30日 102（e）日期1993年8月30日PCT提交1992年2月28日PCT公布。出版物WO92 / 15558 本发明涉及由式（1）表示的茚满衍生物或其药学上可接受的盐：其中R1表示C1〜C12烷基，苄基，苯乙烯基，萘基，任意取代苯基或任选取代的噻吩基; R 2表示羧基，C 1〜C 4烷氧基羰基，Y表示 - （CH 2）p - （其中p表示0〜5的整数），-CO-（CH 2）q DIFFERENCE，-CH（OH） - （CH 2）q DIFFERENCE，（其中q表示1至4的整数，符号DIFFERENCE表示与R 2的连接），甲醛或亚乙基; n表示1〜4的整数]。根据本发明的化合物有效地拮抗血栓素A2的作用，因此可用于治疗和预防由血栓素A2引起的疾病，例如血管紧张素，血管痉挛，哮喘等。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式